Drug intelligence / Profile preview

Triaminic

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Triaminic is a brand of over-the-counter (OTC) combination medications primarily used to treat symptoms associated with the common cold, influenza, and respiratory allergies. The product line includes various formulations tailored for pediatric and adult use, typically containing a combination of active ingredients such as antihistamines (e.g., chlorpheniramine, diphenhydramine), nasal decongestants (e.g., phenylephrine, pseudoephedrine), cough suppressants (e.g., dextromethorphan), and analgesics/antipyretics (e.g., acetaminophen). These components work through distinct mechanisms: antihistamines antagonize H1 receptors to reduce allergic responses; decongestants act as alpha-adrenergic agonists to constrict nasal blood vessels; cough suppressants act on the medullary cough center; and analgesics inhibit prostaglandin synthesis. Originally marketed by Novartis, the brand is currently distributed by GSK Consumer Healthcare.

Brand names
Triaminic
02

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Triaminic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triaminic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call